Equities research analysts forecast that Sunesis Pharmaceuticals (NASDAQ:SNSS) will announce ($0.29) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Sunesis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.27). Sunesis Pharmaceuticals reported earnings per share of ($0.47) during the same quarter last year, which would suggest a positive year-over-year growth rate of 38.3%. The firm is scheduled to announce its next earnings results on Monday, May 14th.
On average, analysts expect that Sunesis Pharmaceuticals will report full year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($0.94). For the next year, analysts anticipate that the company will post earnings of ($1.16) per share, with EPS estimates ranging from ($1.16) to ($1.15). Zacks’ earnings per share averages are an average based on a survey of analysts that follow Sunesis Pharmaceuticals.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.08.
Several equities analysts have recently issued reports on SNSS shares. ValuEngine cut Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research cut Sunesis Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 14th. Cantor Fitzgerald set a $3.00 price objective on Sunesis Pharmaceuticals and gave the company a “hold” rating in a report on Monday, December 11th. Wells Fargo raised Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price objective for the company from $2.86 to $2.48 in a report on Monday, December 11th. Finally, Oppenheimer started coverage on Sunesis Pharmaceuticals in a report on Thursday, December 14th. They issued a “buy” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $4.00.
Shares of SNSS stock traded down $0.11 on Friday, hitting $2.48. The company had a trading volume of 154,911 shares, compared to its average volume of 302,261. The stock has a market cap of $93.77, a PE ratio of -1.71 and a beta of 1.81. Sunesis Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $7.69.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vatera Holdings LLC acquired a new position in Sunesis Pharmaceuticals in the 4th quarter worth about $673,000. Wells Fargo & Company MN raised its holdings in Sunesis Pharmaceuticals by 127.6% in the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 53,396 shares during the period. Vanguard Group Inc. raised its holdings in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares during the period. BlackRock Inc. raised its holdings in Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 11,351 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 64,343 shares during the period. 53.04% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Sunesis Pharmaceuticals (SNSS) to Post -$0.29 Earnings Per Share” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/06/brokerages-anticipate-sunesis-pharmaceuticals-snss-to-post-0-29-earnings-per-share.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.